Hosted on MSN5d
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
Eli Lilly and Company LLY reported third-quarter 2024 adjusted earnings per share (“EPS”) of $1.18, which missed the Zacks ...
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Investor's Business Daily on MSN6d
Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs
Eli Lilly earnings and revenue missed Q3 views, with sales light for its diabetes and weight-loss drugs. Eli Lilly stock dived Wednesday.
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Evening Chronicle20d
Nasty side effects of weight loss jabs to spot as Government reveals new plan for unemployed
Weight loss jabs could soon be given to tens of thousands of people in the UK. It is planned the new scheme would lower rates of obesity and ease the burden on the NHS - but people are being ...
MedPage Today28d
Tirzepatide Shortage Resolved; Compounder Sues FDA; Menopause Mistaken as Dementia
Certain dosages of the GLP-1 receptor agonists dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy), and liraglutide (Victoza, Saxenda) are still in shortage. Bothersome menopause symptoms like ...